Leerink Partnrs Has Pessimistic View of Illumina Q4 Earnings

Illumina, Inc. (NASDAQ:ILMN) – Stock analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for Illumina in a note issued to investors on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will post earnings per share of $1.24 for the quarter, down from their previous forecast of $1.25. The consensus estimate for Illumina’s current full-year earnings is $4.11 per share. Leerink Partnrs also issued estimates for Illumina’s FY2026 earnings at $4.90 EPS.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter last year, the company earned $0.33 EPS. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year.

A number of other research analysts have also commented on the company. Stephens raised their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Barclays boosted their price target on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Robert W. Baird increased their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Leerink Partners raised their price objective on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price for the company in a research report on Thursday, October 17th. Eight equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $165.95.

Illumina Stock Up 0.4 %

ILMN opened at $139.68 on Wednesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina has a 12 month low of $100.08 and a 12 month high of $156.66. The stock’s 50 day moving average price is $141.37 and its 200 day moving average price is $132.08. The stock has a market cap of $22.15 billion, a P/E ratio of -14.02 and a beta of 1.11.

Institutional Trading of Illumina

Several large investors have recently added to or reduced their stakes in ILMN. Versant Capital Management Inc grew its holdings in shares of Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares in the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares during the period. Massmutual Trust Co. FSB ADV lifted its position in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Illumina in the second quarter worth approximately $61,000. Finally, Private Trust Co. NA boosted its holdings in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.